Ask the
Experts
Melissa Alsina, MD
 
Decisions in the Clinic: Treating Patients With Multiple Myeloma
 
Melissa Alsina, MD

Practice Community

Tampa, FL


Practice Niche

Hematology

Hospital and Institutional Affiliations

Associate Professor of Medicine, Blood and Marrow Transplant and Cellular Immunology Program
H. Lee Moffitt Cancer Center

 

How is the treatment of multiple myeloma changing, particularly as newer agents receive approval or expanded indications (eg, daratumumab granted Priority Review for the first line, denosumab approved to prevent skeletal-related events [SREs])?

 

There have been tremendous advances in the treatment of both newly diagnosed and relapsed myeloma, which have had an important impact on survival and quality of life. However, there is still work to be done, and, fortunately, the collaborations of clinical and basic researchers, pharma, and patients and their families have enabled the momentum to continue. We continue to see new drugs being approved and move quickly to the upfront setting.

 

How has maintenance therapy changed, and what is its role now for patients with multiple myeloma?

 

I think at this time is clear that lenalidomide maintenance in myeloma is important both in the transplant and non-transplant setting. This is based on several randomized studies showing both a progression-free survival and overall survival benefit. There are ongoing studies trying to improve the results with lenalidomide, using for example lenalidomide and ixazomib. Very important to consider how maintenance therapy may affect quality of life and do necessary adjustments so that patents can enjoy longer lives free of myeloma and with quality.


 

Where are we now with CAR-T therapy for multiple myeloma? What can be expected in the near future, in terms of incorporating it into practice?

 

Several studies have shown very good responses ranging from 60% to 90% with BCMA [B-cell maturation antigen] CAR-T therapy in relapsed/refractory myeloma. I think initially it will be approve for relapsed/refractory disease, but will start evaluating the role of this therapy in earlier stages of the disease, particularly in patient populations where long PFS [progression-free survival] and OS [overall survival] still remain a challenge, such as high-risk myeloma or plasma cell leukemia.

 

Do you think immune checkpoint inhibition will have a place in the treatment landscape for multiple myeloma, given the increased risk of death in clinical trials? Is the mechanism for the increased risk of death known?

 

The increased risk of death is not well-understood, and it seems to be when these agents are given in combination with immunomodulatory drugs (IMiDs). I do not think these drugs will have a role in the treatment of myeloma, at least in combination with IMiDs.


 

What new approaches are you excited about for the treatment of multiple myeloma in the future?

 

I am very excited about BCMA CAR-T therapy. I am also excited about ongoing research to determine the role of minimal residual disease evaluation in treatment decisions, as well as the incorporation of an anti-CD38 monoclonal antibody as part of induction and maintenance therapy.


 

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs